Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

Contributed by: Business Wire

Tags

Science

Biotechnology

Research

Pharmaceutical

Oncology

General Health

Health

Clinical Trials

STC-1010

More Like This

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

George Alzeeb, PhD, Innovation Manager at Brenus Pharma, presenting the company’s latest preclinical data on STC-1010 — an off-the-shelf vaccine-based immunotherapy — during the Late-Breaking session at the American Association for Cancer Research (AACR) Annual Meeting 2025. This poster highlights the potential of STC-1010 to induce a robust anti-tumor response, supporting Brenus Pharma’s novel approach in immuno-oncology and clincial development.

AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy